Clinical Trial Update: Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and pharmacokinetics of the HIV broadly neutralizing antibody VRC07-523LS in healthy, HIV-uninfected adults; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC07-523LS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2022-03-07